Literature DB >> 8968795

Multiple endocrine neoplasia type 1 associated with malignant lymphoma and other complications.

H Toshimori1, M Okamoto, K Nakatsuru, H Hidaka, H Yamaguchi, Y Ushiroda, A Kisanuki, H Tsubouchi, A Sumiyoshi, S Matsukura.   

Abstract

A 49-year-old female with multiple endocrine neoplasia (MEN) type 1 associated with malignant lymphoma, lipoma, functioning adenomatous goiter, non-functioning adrenal tumor, polyneuropathy, postoperative primary hyperparathyroidism, and hepatitis B virus was a human T lymphotropic virus type 1 (HTLV-1) carrier. She underwent parathyroidectomy for primary hyperparathyroidism at age 44. At age 49, examinations of the enlarged para-aortic lymph nodes revealed diffuse small non-cleaved B cell lymphoma in stage II, and other various complications were also found. Multiple tumorigenetic factors were considered to be involved in the present case.

Entities:  

Mesh:

Year:  1996        PMID: 8968795     DOI: 10.2169/internalmedicine.35.849

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Authors:  Jeffrey A Norton; Geoffrey Krampitz; Robert T Jensen
Journal:  Surg Oncol Clin N Am       Date:  2015-07-27       Impact factor: 3.495

2.  Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1.

Authors:  Charu Kaiwar; Sarah K Macklin; Jennifer M Gass; Jessica Jackson; Eric W Klee; Stephanie L Hines; John A Stauffer; Paldeep S Atwal
Journal:  Hered Cancer Clin Pract       Date:  2017-07-21       Impact factor: 2.857

3.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.